摘要
支气管哮喘中医学认为其属"哮病"范畴,辨证论治是中医治疗支气管哮喘的优势和特色所在,实现对支气管哮喘中医证候动态定性及定量的把握是提高支气管哮喘临床疗效的关键环节。生物标志物是生物体受刺激或扰动后,生物学介质中可以检测到细胞、生物化学或分子改变;而生物标志物与支气管哮喘中医证候具有一定相关性,其可能是实现支气管哮喘中医证候的定性和量化的突破点,且相关的研究较少,故本文以期找到可以划分各证候的客观参考指标,从而提高支气管哮喘的中医诊疗能力,同时为以后的研究提供参考。
Traditional Chinese medicine of bronchial asthma holds that it belongs to the category of "Xiao". Syndrome differentiation and treatment is the advantage and characteristic of traditional Chinese medicine in the treatment of bronchial asthma. Realizing the dynamic qualitative and quantitative grasp of TCM syndrome of bronchial asthma is the key link to improve the clinical curative effect of bronchial asthma. Biomarkers can detect cellular, biochemical or molecular changes in biological media after stimulation or disturbance of organisms, and biomarkers have certain correlation with TCM syndromes of bronchial asthma, which may be a breakthrough point to realize the qualitative and quantitative diagnosis of TCM syndromes of bronchial asthma, and the related research is less. Therefore, this paper hopes to find an objective reference index which can divide the syndromes,so as to improve the ability of traditional Chinese medicine diagnosis and treatment of bronchial asthma, and provide a reference for future research.
作者
屠新敏
赵欢欢
杨江
林晓红
王明航
TU Xin-min;ZHAO Huan-huan;YANG Jiang;LIN Xiao-hong;WANG Ming-hang(Henan University of Chinese Medicine,Zhengzhou Henan,450000,China;First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,Henan,China)
出处
《时珍国医国药》
CAS
CSCD
北大核心
2020年第5期1212-1214,共3页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(81873278)。
关键词
支气管哮喘
中医证候
生物标志物
Bronchial asthma
Traditional Chinese medicine syndromes
Biomarkers
